Global gene expression profiles of MT knockout and wild-type mice in the condition of doxorubicin-induced cardiomyopathy

Toxicology Letters

Volumn 200, Issue 1-2, 2011, Pages 77-87

  Shuai, Yi ^a,b   Guo, Jun ^a   Dong, Yansheng ^a   Zhong, Weijian ^b   Xiao, Ping ^b   Zhou, Tong ^b   Zhang, Lishi ^c   Peng, Shuangqing ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b SHANGHAI MUNICIPAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

Cardiotoxicity; Doxorubicin; Gene expression profile; Knockout mice; Metallothionein; Microarray

Indexed keywords

DOXORUBICIN; JANUS KINASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROTEIN P53; STAT PROTEIN; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; DRUG RESPONSE; GENE EXPRESSION PROFILING; GENOMICS; GENOTYPE; HEART PROTECTION; MALE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; WILD TYPE;

ANIMALS; CARDIOMYOPATHIES; CREATINE KINASE; DOXORUBICIN; GENE EXPRESSION PROFILING; GENES; L-LACTATE DEHYDROGENASE; MALE; METALLOTHIONEIN; MICE; MICE, KNOCKOUT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TRANSCRIPTION, GENETIC;

ANIMALIA; MUS;

EID: 78650169897     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2010.10.017     Document Type: Article

References (46)

1. Ali M.M., Frei E., Straub J., Breuer A., Wiessler M. Induction of metallothionein by zinc protects from daunorubicin toxicity in rats. Toxicology 2002, 179:85-93.
2. 2+)-ATPase gene transcription. Circ. Res. 2000, 86:8-14.
3. Banerjee D., Onosaka S., Cherian M.G. Immunohistochemical localization of metallothionein in cell nucleus and cytoplasm of rat liver and kidney. Toxicology 1982, 24:95-105.
4. Bishopric N.H., Andreka P., Slepak T., Webster K.A. Molecular mechanisms of apoptosis in the cardiac myocyte. Curr. Opin. Pharmacol. 2001, 1:141-150.
5. Brand M.D., Affourtit C., Esteves T.C., Green K., Lambert A.J., Miwa S., Pakay J.L., Parker N. Mitochondrial superoxide: production, biological effects, and activation of uncoupling proteins. Free Radic. Biol. Med. 2004, 37:755-767.
6. Cannon B., Shabalina I.G., Kramarova T.V., Petrovic N., Nedergaard J. Uncoupling proteins: a role in protection against reactive oxygen species - or not?. Biochim. Biophysi. Acta (BBA) - Bioenerget. 2006, 1757:449-458.
7. Chen B., Peng X., Pentassuglia L., Lim C.C., Sawyer D.B. Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovasc. Toxicol. 2007, 7:114-121.
8. Chien A.J., Moon R.T. WNTS and WNT receptors as therapeutic tools and targets in human disease processes. Front. Biosci. 2007, 12:448-457.
9. Coyle P., Philcox J.C., Carey L.C., Rofe A.M. Metallothionein: the multipurpose protein. Cell Mol. Life Sci. 2002, 59:627-647.
10. Davies K.J., Doroshow J.H. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J. Biol. Chem. 1986, 261:3060-3067.
11. Doroshow J.H., Davies K.J. Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. J. Biol. Chem. 1986, 261:3068-3074.
12. Echtay K.S. Mitochondrial uncoupling proteins-what is their physiological role?. Free Radic. Biol. Med. 2007, 43:1351-1371.
13. Ferreira A.L., Matsubara L.S., Matsubara B.B. Anthracycline-induced cardiotoxicity. Cardiovasc. Hematol. Agents Med. Chem. 2008, 6:278-281.
14. Franco C.A., Liebner S., Gerhardt H. Vascular morphogenesis: a Wnt for every vessel?. Curr. Opin. Genet. Dev. 2009, 19:476-483.
15. Jung K., Reszka R. Mitochondria as subcellular targets for clinically useful anthracyclines. Adv. Drug Deliv. Rev. 2001, 49:87-105.
16. Kang Y.J., Chen Y., Yu A., Voss-McCowan M., Epstein P.N. Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity. J. Clin. Invest. 1997, 100:1501-1506.
17. Kang Y.J., Zhou Z.X., Wang G.W., Buridi A., Klein J.B. Suppression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases. J. Biol. Chem. 2000, 275:13690-13698.
18. Kimura T., Fujita I., Itoh N., Muto N., Nakanishi T., Takahashi K., Azuma J., Tanaka K. Metallothionein acts as a cytoprotectant against doxorubicin toxicity. J. Pharmacol. Exp. Ther. 2000, 292:299-302.
19. Kimura T., Oguro I., Kohroki J., Takehara M., Itoh N., Nakanishi T., Tanaka K. Metallothionein-null mice express altered genes during development. Biochem. Biophys. Res. Commun. 2000, 270:458-461.
20. Leyshon-Sorland K., Stang E. The ultrastructural localization of metallothionein in cadmium exposed rat liver. Histochem. J. 1993, 25:857-864.
21. McLeod C.J., Aziz A., Hoyt R.F., McCoy J.P., Sack M.N. Uncoupling proteins 2 and 3 function in concert to augment tolerance to cardiac ischemia. J. Biol. Chem. 2005, 280:33470-33476.
22. Merten K.E., Feng W., Zhang L., Pierce W., Cai J., Klein J.B., Kang Y.J. Modulation of cytochrome C oxidase-va is possibly involved in metallothionein protection from doxorubicin cardiotoxicity. J. Pharmacol. Exp. Ther. 2005, 315:1314-1319.
23. Minotti G. Cardiotoxicity of antitumor drugs. Toxicol.Lett. 2007, 172:S5-S15.
24. Miura N., Koizumi S. Gene expression profiles in the liver and kidney of metallothionein-null mice. Biochem. Biophys. Res. Commun. 2005, 332:949-955.
25. Miura N., Naganuma A. Metallothionein mediates gene expression of 3.1 mRNA (PTZ17) related to epileptic seizure. FEBS Lett. 2000, 479:146-148.
26. Mukhopadhyay P., Rajesh M., Batkai S., Kashiwaya Y., Hasko G., Liaudet L., Szabo C., Pacher P. Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am. J. Physiol. Heart Circ. Physiol. 2009, 296:H1466-1483.
27. Mullins J.E., Fuentealba I.C. Immunohistochemical detection of metallothionein in liver, duodenum and kidney after dietary copper-overload in rats. Histol. Histopathol. 1998, 13:627-633.
28. Nadtochiy S.M., Tompkins A.J., Brookes P.S. Different mechanisms of mitochondrial proton leak in ischaemia/reperfusion injury and preconditioning: implications for pathology and cardioprotection. Biochem. J. 2006, 395:611-618.
29. Olson R.D., Gambliel H.A., Vestal R.E., Shadle S.E., Charlier H.A., Cusack B.J. Doxorubicin cardiac dysfunction: effects on calcium regulatory proteins, sarcoplasmic reticulum, and triiodothyronine. Cardiovasc. Toxicol. 2005, 5:269-283.
30. Olson R.D., Mushlin P.S. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J. 1990, 4:3076-3086.
31. Satoh M., Naganuma A., Imura N. Involvement of cardiac metallothionein in prevention of adriamycin induced lipid peroxidation in the heart. Toxicology 1988, 53:231-237.
32. Satoh M., Naganuma A., Imura N. Modulation of adriamycin toxicity by tissue-specific induction of metallothionein synthesis in mice. Life Sci. 2000, 67:627-634.
33. Shuai Y., Guo J.-B., Peng S.-Q., Zhang L.-S., Guo J., Han G., Dong Y.-S. Metallothionein protects against doxorubicin-induced cardiomyopathy through inhibition of superoxide generation and related nitrosative impairment. Toxicol. Lett. 2007, 170:66-74.
34. Simunek T., Sterba M., Popelova O., Adamcova M., Hrdina R., Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol. Rep. 2009, 61:154-171.
35. Sun X., Zhou Z., Kang Y.J. Attenuation of doxorubicin chronic toxicity in metallothionein-overexpressing transgenic mouse heart. Cancer Res. 2001, 61:3382-3387.
36. Takemura G., Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog. Cardiovasc. Dis. 2007, 49:330-352.
37. Thirumoorthy N., Manisenthil Kumar K.T., Shyam Sundar A., Panayappan L., Chatterjee M. Metallothionein: an overview. World J. Gastroenterol. 2007, 13:993-996.
38. van de Schans V.A.M., Smits J.F.M., Blankesteijn W.M. The Wnt/frizzled pathway in cardiovascular development and disease: friend or foe?. Eur. J. Pharmacol. 2008, 585:338-345.
39. Vlad A., Röhrs S., Klein-Hitpass L., Müller O. The first five years of the Wnt targetome. Cell. Signal. 2008, 20:795-802.
40. Wang G.W., Kang Y.J. Inhibition of doxorubicin toxicity in cultured neonatal mouse cardiomyocytes with elevated metallothionein levels. J. Pharmacol. Exp. Ther. 1999, 288:938-944.
41. Wang G.W., Klein J.B., Kang Y.J. Metallothionein inhibits doxorubicin-induced mitochondrial cytochrome c release and caspase-3 activation in cardiomyocytes. J. Pharmacol. Exp. Ther. 2001, 298:461-468.
42. Wang Y. Mitogen-activated protein kinases in heart development and diseases. Circulation 2007, 116:1413-1423.
43. Ye B., Maret W., Vallee B.L. Zinc metallothionein imported into liver mitochondria modulates respiration. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:2317-2322.
44. Yi X., Bekeredjian R., DeFilippis N.J., Siddiquee Z., Fernandez E., Shohet R.V. Transcriptional analysis of doxorubicin-induced cardiotoxicity. Am. J. Physiol. Heart Circ. Physiol. 2006, 290:H1098-1102.
45. Zhou Z., Kang Y.J. Immunocytochemical localization of metallothionein and its relation to doxorubicin toxicity in transgenic mouse heart. Am. J. Pathol. 2000, 156:1653-1662.
46. Zhu W., Zou Y., Aikawa R., Harada K., Kudoh S., Uozumi H., Hayashi D., Gu Y., Yamazaki T., Nagai R., Yazaki Y., Komuro I. MAPK superfamily plays an important role in daunomycin-induced apoptosis of cardiac myocytes. Circulation 1999, 100:2100-2107.